Exuviance

The whole story begins in a hospital, not a lab bench at a cosmetics company. Two researchers at Temple University in Philadelphia were chasing treatments for severe, scaling skin disease, testing formula after formula on patients struggling with dryness and thickened skin. When they hit on a mixture that worked, they at first made it by hand, then handed the recipe to nearby pharmacies to compound. That improvised supply chain was the embryo of an entire skincare category.

What the two doctors had stumbled onto was the therapeutic power of alpha hydroxy acids. In 1974 they co-authored the first published scientific paper on AHAs in dermatology, and a patent followed in 1975. Their research showed these acids could speed the skin's natural turnover and coax aged or damaged skin into renewing itself, a finding that quietly rewrote what topical skincare could promise. Over the following decades their work accumulated into more than a hundred patents and earned them the Dermatology Foundation's Discovery Award, recognition usually reserved for breakthroughs in treating disease.

The company they formed grew into a small family of brands. Exuviance became the consumer-facing line of acid serums, peels, and moisturizers, while its sibling NeoStrata served professional channels, all built on the founders' homegrown chemistry. The same team later pioneered polyhydroxy acids, gentler cousins of AHAs that exfoliate without the same sting, giving sensitive-skinned users a route into acid skincare. The business eventually passed to Johnson & Johnson's consumer arm, which has since spun off into the independent company Kenvue.

The quiet irony is that the brand that effectively invented the glow-acid category has spent years being outshone by louder, more heavily marketed acid lines. Its presentation reads clinical and a touch old-fashioned, but the provenance is unimpeachable. These founders didn't adopt the AHA story; they authored it, and the formulas still carry that authority.

Sources:[1][2][3][4]